Lung Cancer Stage IV Clinical Trial
Official title:
Resilience Measurement, Prediction, and Its Role in Older Adults With Late-Stage Lung Cancer
The purpose of this study to test measures of physical and psychological resilience while using Self-System therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).
The investigator will examine the feasibility of delivering measures of psychological and physical resilience while delivering the SST intervention. The investigator will also examine whether participation in SST can help alleviate symptoms of depression and distress while helping improve overall physical functioning in older adults with advanced lung cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03668496 -
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
|
Phase 3 | |
| Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
| Recruiting |
NCT05497973 -
Psychosocial eHealth in Advanced Lung Cancer
|
N/A | |
| Recruiting |
NCT06076005 -
Lung Cancer ID (Identity) Study
|
||
| Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
| Completed |
NCT03529851 -
Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients
|
N/A | |
| Completed |
NCT03558165 -
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
|
||
| Completed |
NCT03076164 -
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03153358 -
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
|
Phase 2 | |
| Recruiting |
NCT04595734 -
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
|
||
| Recruiting |
NCT04519983 -
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
|
Phase 2 | |
| Not yet recruiting |
NCT05701384 -
Lazertinib 160mg in EGFR T790M NSCLC
|
Phase 2 | |
| Withdrawn |
NCT03409341 -
Personalizing Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT03728361 -
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06024941 -
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04669223 -
Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion
|
N/A | |
| Recruiting |
NCT05996263 -
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
|
||
| Completed |
NCT04057196 -
Self-System Therapy for Older Adults With Lung Cancer
|
N/A | |
| Recruiting |
NCT06000358 -
The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer
|
N/A |